

WS1234172 from Pfizer and grants AI 048079, AI 072648, and AI 122176 from the National Institutes of Health and the Central New York Community Foundation.

**Trial Registration** Prospective Study of Rapamycin for the Treatment of SLE; ClinicalTrials.gov Identifier: NCT00779194. Treatment trial of SLE with N-acetylcysteine; ClinicalTrials.gov identifier: NCT00775476.

**Lay summary** Rapamycin, also called as sirolimus, has been newly identified as a new treatment with promising clinical effectiveness and well-defined mechanism of active in patients with moderate to severe SLE.

## REFERENCES

- Lai, Z. *et al.* Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. *Lancet* 2018;**391**: 1186–1196
- Piranavan, P., and Perl, A. Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - A 21-year follow-up study of 73 patients. *Clin. Immunol.* 2021;**229**: 108781
- Mao, Z. *et al.* Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis. *Rheumatology*, 2022; keac037
- Perl, A. Mechanistic Target of Rapamycin Pathway Activation in Rheumatic Diseases. *Nat. Rev. Rheumatol.* 2016; **12**, 169–182
- Yoshida, S. *et al.* Redox Regulates Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity by Modulating the TSC1/TSC2-Rheb GTPase Pathway. *J. Biol. Chem.* 2011;**286**, 32651–32660
- Lai, Z.-W. *et al.* N-acetylcysteine reduces disease activity by blocking mTOR in T cells of lupus patients. *Arthritis Rheum.* 2012;**64**, 2937–2946
- Perl, A. *et al.* Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. *Metabolomics* 2015;**11**, 1157–1174

## Lupus-Targeted Therapeutics

1204

### IMPROVING LYMPHATIC FUNCTION TO REDUCE B CELL RESPONSES IN LUPUS

<sup>1,2,††</sup>William G Ambler\*, <sup>1,3</sup>Mir Howlader, <sup>1,4,†</sup>Madhavi Latha S Chalasani, <sup>1</sup>Ethan S Seltzer, <sup>1,4</sup>JiHyun Sim, <sup>4</sup>Jinyeon Shin, <sup>1,6,‡</sup>Noa Schwartz, <sup>1,7,†</sup>Dragos Dasoveanu, <sup>8</sup>Camila B Carballo, <sup>5,†</sup>Ecem Sevim, <sup>2,6</sup>Salma Siddique, <sup>††</sup>, <sup>8,9</sup>Scott Rodeo, <sup>††</sup>Doruk Erkan, <sup>9</sup>Raghu P Kataru, <sup>5</sup>Babak Mehrara, <sup>1,2,4,6,10</sup>Theresa T Lu\*. <sup>1</sup>Autoimmunity and Inflammation Program, Hospital for Special Surgery Research Institute; New York, NY, USA; <sup>2</sup>Pediatric Rheumatology, Department of Medicine, Hospital for Special Surgery; New York, NY, USA; <sup>3</sup>Biochemistry, Structural Biology, Cell Biology, Developmental Biology and Molecular Biology Graduate Program, Weill Cornell Medicine; New York, NY, USA; <sup>4</sup>Department of Microbiology and Immunology, Weill Cornell Medicine; New York, NY, USA; <sup>5</sup>Division of Plastic and Reconstructive Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center; New York, NY, USA; <sup>6</sup>Rheumatology, Department of Medicine, Hospital for Special Surgery; New York, NY, USA; <sup>7</sup>Physiology, Biophysics, and Systems Biology Graduate Program, Weill Cornell Medicine, New York, NY, USA; <sup>8</sup>Orthopedic Soft Tissue Research Program, Hospital for Special Surgery Research Institute; New York, NY, USA; <sup>9</sup>Department of Orthopedics, Hospital for Special Surgery; New York, NY, USA; <sup>10</sup>Department of Pediatrics, Weill Cornell Medicine; New York, NY, USA; <sup>††</sup>Current address: NIAMS, Bethesda, MD, USA; <sup>†</sup>Current address: Mnemo Therapeutics; Princeton, NJ, USA; <sup>‡</sup>Current address Department of Medicine (Rheumatology), Albert Einstein College of Medicine/Montefiore Medical Center; Bronx, NY, USA; <sup>§</sup>Current address Department of Medicine, Montefiore Medical Center; Bronx, NY, USA; <sup>¶</sup>Current address Department of Cancer Immunology, Genentech; South San Francisco, CA, USA; <sup>†††</sup>Current address Nemours Hospital for Children, Wilmington, DE, USA

10.1136/lupus-2022-lupus21century.86

**Background** In SLE, that ultraviolet radiation exposure can induce both photosensitive skin responses and increased auto-antibody titers suggests a critical and targetable role for the communication from skin to draining lymph nodes in regulating lymph node B cell responses. Lymphatic vessels bring cells and signals from skin to draining lymph nodes to regulate

immunity and dysfunction of lymphatic flow has the potential to alter immunity. Here we examine lymphatic flow function in SLE humans and models, showing that lymphatic flow from skin to lymph nodes is compromised. that improving lymphatic flow by manual lymphatic drainage (MLD) or in a transgenic model reduces lymph node B cell responses, and delineate the mechanistic underpinnings of how lymphatic flow modulates draining lymph node function.

**Methods** We examined lymphatic vessel luminal area considered to be reflective of lymphatic flow function in healthy controls, SLE, and control disease (anti-phospholipid antibody + non-SLE patients) by immunohistochemistry and image analysis. We examined lymphatic function and performed manual lymphatic drainage in both MRL/lpr and imiquimod-induced lupus models. Lymphatic function was assessed by Evans blue tissue clearance assays and lymph node function was assessed by mainly by flow cytometry. Lymphatic flow was improved by either manual lymphatic drainage, adapted to mice based on techniques used in humans, or in a transgenic PTEN<sup>fl/fl</sup> Flt4-Cre<sup>ER</sup> model with increased lymphatic numbers and function.

**Results** SLE patient skin showed increased lymphatic vessel lumen size in skin and multiple SLE mouse models showed reduced clearance of intradermally-injected Evans blue, both suggesting reduced lymphatic flow in SLE. Improving lymphatic flow by manual lymphatic drainage (MLD) or in imiquimod-treated PTEN<sup>fl/fl</sup> Flt4-Cre<sup>ER</sup> mice reduced both cutaneous photosensitivity and lymph node germinal center and plasma cells.

Mechanistically, improved flow restrains B cell responses by upregulating lymph node fibroblastic reticular cell CCL2, which modulates monocyte phenotype to limit germinal center and plasma cell numbers.

**Conclusions** Our results suggest a scenario whereby dysfunctional communication between the skin and the immune system alters lymph node function to modulate disease, point to a lymphatic flow-lymph node stromal axis as a therapeutic target, and suggest the possibility of manual lymphatic drainage, an existing treatment modality used in breast adjunctive treatment in SLE.

## Lupus 21<sup>st</sup> Century 2022 Abstract

1205

### TREATMENT OF LUPUS-PRONE BXS<sub>B</sub> MICE WITH A MODULATABLE CAR T CELL SYSTEM TARGETING CD19

<sup>1</sup>Ivo Rimann, <sup>1</sup>Hua Huang, <sup>1</sup>Parker Mace, <sup>1</sup>Rosana Gonzalez-Quintal, <sup>1</sup>Eduardo Laborda, <sup>2</sup>Sophie Viaud, <sup>1</sup>Hannah Mora, <sup>1</sup>Argyrios N Theofilopoulos, <sup>2</sup>Travis S Young, <sup>1</sup>Dwight H Kono. <sup>1</sup>The Scripps Research Institute; <sup>2</sup>Calibr at Scripps Research

10.1136/lupus-2022-lupus21century.87

Chimeric antigen receptor (CAR) T cells directed against CD19 have demonstrated efficacy in treating active lupus in both human and mouse lupus. However, a significant limitation of this approach is immunodeficiency due to the long-term depletion of B cells. To address this issue, we studied the potential of a switchable CAR (sCAR) T cell system targeting CD19 to transiently eliminate B cells and provide therapeutic benefit with less immunosuppression. This approach consists of a CAR that, instead of targeting CD19 directly, binds to a soluble antiCD19 Fab switch with a short